A ruling that the right to strike also has limits it cannot cross
A case reflecting the biopharmaceutical industry's unique characteristics in legal interpretation

Kim Giseon, professor at Chungnam National University Law School

Kim Giseon, professor at Chungnam National University Law School

View original image

Recently, in an appeal concerning an injunction barring industrial action at Samsung Biologics, the court issued a meaningful decision recognizing the importance of continuity in biopharmaceutical production processes. It expanded the scope of work exempt from strike action from the three downstream processes recognized by the court of first instance to nine key processes, including cell culture and purification. The decision is significant because it went beyond simply determining who was right or wrong in an individual labor dispute and clarified the extent to which the right to strike may be exercised in the advanced biotechnology industry.


Article 38(2) of the current Trade Union and Labor Relations Adjustment Act stipulates that work necessary to prevent damage to facilities or the deterioration or decay of raw materials or products must be carried out as usual even during industrial action. This reflects the legislature's clear determination that while the three labor rights are guaranteed, their exercise must not exceed the limits set by law.


Biopharmaceutical production operates on principles markedly different from those of general manufacturing. The series of processes involved in cultivating living cells and purifying them to produce pharmaceuticals are organically interconnected. If a particular process is halted, raw materials and intermediate products already in use may deteriorate irreversibly, going beyond a simple delay in production. It is difficult to assess the legitimacy of industrial action by the same standards as those applied to general manufacturing while ignoring these industry-specific characteristics.


Reflecting the Distinctive Nature of Interconnected Continuous Processes in Legal Interpretation


One particularly noteworthy aspect of the appellate court's decision is that it did not limit the scope of protective work to the formal maintenance of facilities or downstream processes. The court focused on the distinctive nature of biopharmaceutical production, which consists of interconnected continuous processes, and on the dual nature of those processes. Accordingly, it ruled that even processes involving actual production activities, such as cell culture and purification, must be carried out as usual during industrial action if they are necessary to prevent the deterioration of raw materials and products. This reflects the specific characteristics of the biotechnology industry in the interpretation of labor law.


The right of a trade union to strike is not negated if the action has been approved by a majority of its members and the procedures prescribed by law have been followed. However, the fact that a union may strike and the question of whether that strike is legitimate are entirely separate matters. A union's decision to launch a full-scale strike does not exempt it from its legal obligation to carry out protective work. The fact that a strike was conducted in accordance with the proper procedures does not justify violations of conduct prohibited by the Trade Union and Labor Relations Adjustment Act.


In particular, if halting a production process already underway or reducing the necessary workforce or operating hours creates a risk of deterioration in raw materials or products, it is difficult to regard such action as protected merely as an exercise of the right to strike. The court's decision can be seen as a landmark that clearly defines the legal limits of full-scale strikes in the biotechnology industry. Ultimately, it will be difficult to maintain the belief that labor dispute strategies premised on a complete shutdown of key production processes in the industry are automatically permissible.


Significance of Defining the Limits of Labor Disputes Framed Around a "Complete Production Shutdown"


Biopharmaceuticals are directly connected to patients' lives and health. The risks of a production halt can extend beyond financial losses to a company, affecting global pharmaceutical supply chains and patients' access to treatment. These public-interest considerations must also not be overlooked when assessing industrial action in the biotechnology industry. This decision will serve as an important benchmark for labor relations at domestic biopharmaceutical manufacturing facilities in the future. Trade unions must consider the industry's distinctive characteristics and their legal obligations before exercising their right to take industrial action, while companies must also work to balance the protection of legitimate labor rights with stable pharmaceutical production.


In the biotechnology industry, continuity of production processes is not a management choice but a legal obligation. The right to take industrial action must be respected, but that does not guarantee the right to jeopardize the quality and safety of pharmaceuticals in its name. This is the most important legal message the appellate court's decision leaves for our society.



Kim Giseon, professor at Chungnam National University Law School


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing